Please use this identifier to cite or link to this item:
http://publications.jrc.ec.europa.eu/repository/handle/JRC33606| Title: | Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer |
| Authors: | QU C.f.; SONG E.; LI Y.; RIZVI S.m.a.; RAJA C.; ROSS R; APOSTOLIDIS CHRISTOS; ALLEN Barry J. |
| Editors: | MORGENSTERN ALFRED |
| Citation: | CLINICAL & EXPERIMENTAL METASTASIS vol. 22 p. 575-586 |
| Publisher: | SPRINGER |
| Publication Year: | 2005 |
| JRC N°: | JRC33606 |
| URI: | http://publications.jrc.ec.europa.eu/repository/handle/JRC33606 |
| Type: | Articles in periodicals and books |
| Abstract: | Purpose: The urokinase plasminogen activator (uPA) and its receptor (uPAR) are expressed by pancreatic cancer cells and can be targeted by the plasminogen activator inhibitor type 2 (PAI2). We have labeled PAI2 with 213Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy. |
| JRC Directorate: | Nuclear Safety and Security |
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.